Institutional
CAXTON CORP
CIK 0001388551
$4.0M
Reported AUM
7
Positions
Q1 2026
Period
2026-05-14
Filed
The Brief · CAXTON CORP · Q1 2026
AI · grounded in 13F
CAXTON CORP closed its position in SYRE, reducing its exposure by $292,194. The fund also exited positions in BRD1EUR and CMPX, with losses of $210,058 and $158,386 respectively. To offset these exits, the fund established a new position in ALXO worth $41,996 and increased its holdings in GLD by 9.463%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GLD | SPDR GOLD TR | $396.24 | -3.65% | 29.84% | 133.33% | $3.3M | 81.50% | +659 | +9.5% |
| 2 | BRK/B | BERKSHIRE HATHAWAY INC DEL | — | — | — | — | $348K | 8.66% | +17 | +2.4% |
| 3 | KYTX | KYVERNA THERAPEUTICS INC | $7.47 | -6.04% | 120.35% | -69.93% | $162K | 4.03% | — | HELD |
| 4 | LXEO | LEXEO THERAPEUTICS INC | $4.37 | -8.58% | 12.63% | -67.44% | $80K | 1.99% | — | HELD |
| 5 | XFOR | X4 PHARMACEUTICALS INC | $3.83 | -4.49% | -10.93% | -97.78% | $64K | 1.60% | — | HELD |
| 6 | IKT | INHIBIKASE THERAPEUTICS INC | $1.63 | -1.81% | -16.84% | -88.03% | $48K | 1.19% | — | HELD |
| 7 | ALXO | ALX ONCOLOGY HLDGS INC | $1.54 | -1.28% | 165.98% | -97.37% | $42K | 1.04% | +20,946 | NEW |
| 8 | SYRE | SPYRE THERAPEUTICS INC | $73.65 | -6.15% | 334.00% | -51.94% | — | — | −8,919 | EXITED |
| 9 | BRD1EUR | MIND MEDICINE MINDMED INC | — | — | — | — | — | — | −15,688 | EXITED |
| 10 | CMPX | COMPASS THERAPEUTICS INC | $2.04 | -4.23% | -18.40% | -58.37% | — | — | −29,495 | EXITED |
| 11 | SABS | SAB BIOTHERAPEUTICS INC | $3.38 | -2.59% | 86.74% | -96.59% | — | — | −10,527 | EXITED |
| 12 | CNTX | CONTEXT THERAPEUTICS INC | $1.75 | -13.79% | 163.55% | -74.56% | — | — | −18,403 | EXITED |
Source: SEC EDGAR · accession 0000919574-26-003017. 13F discloses long positions only — shorts, foreign equities, and options are excluded.